130 related articles for article (PubMed ID: 7813120)
21. Ethanol-induced reduction in myocardial oxygen consumption can be attenuated by inhibiting guanylyl cyclase.
Lazar MJ; Patel K; Scholz PM; Weiss HR
J Cardiovasc Pharmacol; 2001 Oct; 38(4):512-9. PubMed ID: 11588521
[TBL] [Abstract][Full Text] [Related]
22. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide.
Weisbrod RM; Griswold MC; Yaghoubi M; Komalavilas P; Lincoln TM; Cohen RA
Br J Pharmacol; 1998 Dec; 125(8):1695-707. PubMed ID: 9886761
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide synthase and cGMP-mediated stimulation of renin secretion.
Sayago CM; Beierwaltes WH
Am J Physiol Regul Integr Comp Physiol; 2001 Oct; 281(4):R1146-51. PubMed ID: 11557622
[TBL] [Abstract][Full Text] [Related]
24. Lack of the nitric oxide-cyclic GMP-potassium channel pathway for the antinociceptive effect of intrathecal zaprinast in a rat formalin test.
Yoon MH; Choi JI; Bae HB; Jeong SW; Chung SS; Yoo KY; Jeong CY; Kim SJ; Chung ST; Kim CM
Neurosci Lett; 2005 Dec; 390(2):114-7. PubMed ID: 16115733
[TBL] [Abstract][Full Text] [Related]
25. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
Leone RJ; Straznicka M; Scholz PM; Weiss HR
Basic Res Cardiol; 2000 Feb; 95(1):28-38. PubMed ID: 10752543
[TBL] [Abstract][Full Text] [Related]
26. Effect of cyclic GMP reduction on regional myocardial mechanics and metabolism in experimental left ventricular hypertrophy.
Guo X; Kedem J; Weiss HR; Tse J; Roitstein A; Scholz PM
J Cardiovasc Pharmacol; 1996 Mar; 27(3):392-400. PubMed ID: 8907801
[TBL] [Abstract][Full Text] [Related]
27. Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats.
Ng SS; Pang CC
Eur J Pharmacol; 1998 Jun; 351(3):323-8. PubMed ID: 9721024
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
[TBL] [Abstract][Full Text] [Related]
29. 8-(4-Chlorophenyl)thio-cyclic AMP is a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA).
Connolly BJ; Willits PB; Warrington BH; Murray KJ
Biochem Pharmacol; 1992 Dec; 44(12):2303-6. PubMed ID: 1335252
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase type 5 inhibition enhances vasorelaxation caused by nitroprusside in guinea pig intact heart and isolated aorta.
Stowe F; Novalija E
J Cardiovasc Pharmacol; 2000 Aug; 36(2):162-8. PubMed ID: 10942156
[TBL] [Abstract][Full Text] [Related]
31. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
Chiu WC; Kedem J; Weiss HR; Tse J; Cheinberg BV; Scholz PM
Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
[TBL] [Abstract][Full Text] [Related]
32. Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites.
Burns F; Pyne NJ
Biochem Biophys Res Commun; 1992 Dec; 189(3):1389-96. PubMed ID: 1336365
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
Matot I; Gozal Y
Chest; 2004 Feb; 125(2):644-51. PubMed ID: 14769749
[TBL] [Abstract][Full Text] [Related]
34. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.
De Garavilla L; Pagani ED; Buchholz RA; Dundore R; Bode DC; Volberg ML; Jackson KN; Pratt P; Silver PJ
Eur J Pharmacol; 1996 Oct; 313(1-2):89-96. PubMed ID: 8905333
[TBL] [Abstract][Full Text] [Related]
35. Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast.
Silver PJ; Pagani ED; de Garavilla L; Van Aller GS; Volberg ML; Pratt PF; Buchholz RA
Eur J Pharmacol; 1991 Jun; 199(1):141-2. PubMed ID: 1654265
[No Abstract] [Full Text] [Related]
36. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Thusu KG; Morin FC; Russell JA; Steinhorn RH
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
[TBL] [Abstract][Full Text] [Related]
37. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases.
Weiss HR; Gong GX; Straznicka M; Yan L; Tse J; Scholz PM
Can J Physiol Pharmacol; 1999 Jun; 77(6):422-31. PubMed ID: 10537228
[TBL] [Abstract][Full Text] [Related]
38. Decreasing cyclic GMP exerts similar positive functional effects on cardiac myocytes regardless of initial level.
Yan L; Huang MW; Scholz PM; Weiss HR
Pharmacology; 2000 Jul; 61(1):51-6. PubMed ID: 10895081
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells.
Papapetropoulos A; Go CY; Murad F; Catravas JD
Br J Pharmacol; 1996 Jan; 117(1):147-55. PubMed ID: 8825356
[TBL] [Abstract][Full Text] [Related]
40. Zaprinast accelerates recovery from established acute renal failure in the rat.
Guan Z; Miller SB; Greenwald JE
Kidney Int; 1995 Jun; 47(6):1569-75. PubMed ID: 7643525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
